NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer
NeoGenomics to Participate in Upcoming June Investor Conferences
NeoGenomics Pays Off 1.25% Convertible Senior Notes
Quarterly report [Sections 13 or 15(d)]
Current report
Definitive proxy statements
View and filter by group or type
